Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1R | P00736 | 15/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034176 | 0.90 | C1R (0.43) | C1RMAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL4268147 | 0.88 | C1R (0.47) | C1RMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4264585 | 0.87 | C1R (0.47) | C1RMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4264396 | 0.87 | C1R (0.46) | C1RMAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL4259210 | 0.87 | MAPT (0.46) | C1RMAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL4263346 | 0.85 | C1R (0.43) | C1RMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4260423 | 0.84 | C1R (0.51) | C1RMAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL4266487 | 0.84 | C1R (0.43) | C1RMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4260532 | 0.84 | C1R (0.43) | C1RMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4262993 | 0.84 | C1R (0.43) | C1RMAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446125-B1 | THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY | ALIZYME THERAPEUTICS LTD (GB) | 2009-04-29 | — | — | EP | claimed |
| US-20090029978-A1 | THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY | ALIZYME THERAPEUTICS LIMITED (GB) | 2009-01-29 | — | — | US | claimed |
| US-7407954-B2 | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-08-05 | — | — | US | claimed |
| US-20050075336-A1 | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity | NORGINE B.V. (NL) | 2005-04-07 | — | — | US | claimed |
| EP-1446125-B1 | THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY | ALIZYME THERAPEUTICS LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
| US-20090029978-A1 | THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY | ALIZYME THERAPEUTICS LIMITED (GB) | 2009-01-29 | — | — | US | disclosed |
| US-7407954-B2 | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-20050075336-A1 | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity | NORGINE B.V. (NL) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075336-A1 | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity | LPL, LIPE, LIPC | C1R 3110/4885MAPT 4743/4885ALDH1A1 281/4885 |
| US-20090029978-A1 | THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY | LPL, LIPE, LIPC | C1R 3110/4885MAPT 4743/4885ALDH1A1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.